CD28 and neoplasm: Such broadly expressed tumor antigens may be more amenable to targeting with a CD28 TCE, with the natural avidity of the 2+1 format increasing the pool of antigens with therapeutic potential beyond the limited number of tumor-associated targets interrogated using CD3 TCEs.